DEF6 expression in ovarian carcinoma correlates with poor patient survival

Phui Ly Liew, Chih Yeu Fang, Yu Chieh Lee, Yi Chih Lee, Chi Long Chen, Jan Show Chu

研究成果: 雜誌貢獻文章

2 引文 (Scopus)

摘要

Background: Increased expression of DEF6 is correlated with the malignant behavior of various cancers. Both DEF6 and p16 contribute to the regulation of cell cycle progression, and p53 plays important role in the cell cycle checkpoints. This study was designed to elucidate the prognostic significance of DEF6, p53 and p16 immunoexpressions in different histology subtypes of ovarian carcinoma. Methods: Immunohistochemistry results of DEF6, p53 and p16 on ovarian carcinoma were compared with histology subtypes, clinical data, overall survival (OS) and disease-free survival (DFS) by Cox regression and Kaplan-Meier analysis. Results: We studied 180 cases of ovarian carcinomas (75 high-grade serous, 41 clear cell, 36 mucinous and 28 endometrioid), including 109 FIGO stage I-II cases and 71 FIGO stage III-IV cases. Ovarian carcinomas positive for both DEF6 and p16 expression were associated with the worst OS (P = 0.027) and DFS (P = 0.023), whereas those negative for both DEF6 and p16 had the best OS and DFS. Aberrant p53 expression combined with positive DEF6 was associated with worst OS (P = 0.031) and DFS (P = 0.028). Kaplan-Meier analysis showed that significantly shorter survival rates were seen in patients with high expressions of DEF6 (P = 0.008) and p16 (P = 0.022). Patients with aberrant p53 expression in high-grade serous carcinoma (P = 0.012) and patients with high DEF6 expression in clear cell carcinoma (P = 0.001) were also associated with shorter overall survival. In univariate analysis, FIGO stage, DEF6 and p16 were associated with poor prognosis. DEF6 expression was the only independent prognostic factor correlated with shorted OS (HR 2.115; P = 0.025) and DFS (HR 2.248; P = 0.016) upon multivariate analysis. Conclusions: DEF6 expression may serve as an independent prognostic factor, and interacted positively with p16 toward high tumor stage and shorter survival.
原文英語
文章編號68
期刊Diagnostic Pathology
11
發行號1
DOIs
出版狀態已發佈 - 八月 3 2016

指紋

Carcinoma
Disease-Free Survival
Survival
Kaplan-Meier Estimate
Histology
Cell Cycle Checkpoints
Neoplasms
Cell Cycle
Multivariate Analysis
Survival Rate
Immunohistochemistry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

引用此文

DEF6 expression in ovarian carcinoma correlates with poor patient survival. / Liew, Phui Ly; Fang, Chih Yeu; Lee, Yu Chieh; Lee, Yi Chih; Chen, Chi Long; Chu, Jan Show.

於: Diagnostic Pathology, 卷 11, 編號 1, 68, 03.08.2016.

研究成果: 雜誌貢獻文章

Liew, Phui Ly ; Fang, Chih Yeu ; Lee, Yu Chieh ; Lee, Yi Chih ; Chen, Chi Long ; Chu, Jan Show. / DEF6 expression in ovarian carcinoma correlates with poor patient survival. 於: Diagnostic Pathology. 2016 ; 卷 11, 編號 1.
@article{cbffa757c0474dbe954f97c471b73640,
title = "DEF6 expression in ovarian carcinoma correlates with poor patient survival",
abstract = "Background: Increased expression of DEF6 is correlated with the malignant behavior of various cancers. Both DEF6 and p16 contribute to the regulation of cell cycle progression, and p53 plays important role in the cell cycle checkpoints. This study was designed to elucidate the prognostic significance of DEF6, p53 and p16 immunoexpressions in different histology subtypes of ovarian carcinoma. Methods: Immunohistochemistry results of DEF6, p53 and p16 on ovarian carcinoma were compared with histology subtypes, clinical data, overall survival (OS) and disease-free survival (DFS) by Cox regression and Kaplan-Meier analysis. Results: We studied 180 cases of ovarian carcinomas (75 high-grade serous, 41 clear cell, 36 mucinous and 28 endometrioid), including 109 FIGO stage I-II cases and 71 FIGO stage III-IV cases. Ovarian carcinomas positive for both DEF6 and p16 expression were associated with the worst OS (P = 0.027) and DFS (P = 0.023), whereas those negative for both DEF6 and p16 had the best OS and DFS. Aberrant p53 expression combined with positive DEF6 was associated with worst OS (P = 0.031) and DFS (P = 0.028). Kaplan-Meier analysis showed that significantly shorter survival rates were seen in patients with high expressions of DEF6 (P = 0.008) and p16 (P = 0.022). Patients with aberrant p53 expression in high-grade serous carcinoma (P = 0.012) and patients with high DEF6 expression in clear cell carcinoma (P = 0.001) were also associated with shorter overall survival. In univariate analysis, FIGO stage, DEF6 and p16 were associated with poor prognosis. DEF6 expression was the only independent prognostic factor correlated with shorted OS (HR 2.115; P = 0.025) and DFS (HR 2.248; P = 0.016) upon multivariate analysis. Conclusions: DEF6 expression may serve as an independent prognostic factor, and interacted positively with p16 toward high tumor stage and shorter survival.",
keywords = "DEF6, Ovarian carcinoma, P16, Prognosis",
author = "Liew, {Phui Ly} and Fang, {Chih Yeu} and Lee, {Yu Chieh} and Lee, {Yi Chih} and Chen, {Chi Long} and Chu, {Jan Show}",
year = "2016",
month = "8",
day = "3",
doi = "10.1186/s13000-016-0518-y",
language = "English",
volume = "11",
journal = "Diagnostic Pathology",
issn = "1746-1596",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - DEF6 expression in ovarian carcinoma correlates with poor patient survival

AU - Liew, Phui Ly

AU - Fang, Chih Yeu

AU - Lee, Yu Chieh

AU - Lee, Yi Chih

AU - Chen, Chi Long

AU - Chu, Jan Show

PY - 2016/8/3

Y1 - 2016/8/3

N2 - Background: Increased expression of DEF6 is correlated with the malignant behavior of various cancers. Both DEF6 and p16 contribute to the regulation of cell cycle progression, and p53 plays important role in the cell cycle checkpoints. This study was designed to elucidate the prognostic significance of DEF6, p53 and p16 immunoexpressions in different histology subtypes of ovarian carcinoma. Methods: Immunohistochemistry results of DEF6, p53 and p16 on ovarian carcinoma were compared with histology subtypes, clinical data, overall survival (OS) and disease-free survival (DFS) by Cox regression and Kaplan-Meier analysis. Results: We studied 180 cases of ovarian carcinomas (75 high-grade serous, 41 clear cell, 36 mucinous and 28 endometrioid), including 109 FIGO stage I-II cases and 71 FIGO stage III-IV cases. Ovarian carcinomas positive for both DEF6 and p16 expression were associated with the worst OS (P = 0.027) and DFS (P = 0.023), whereas those negative for both DEF6 and p16 had the best OS and DFS. Aberrant p53 expression combined with positive DEF6 was associated with worst OS (P = 0.031) and DFS (P = 0.028). Kaplan-Meier analysis showed that significantly shorter survival rates were seen in patients with high expressions of DEF6 (P = 0.008) and p16 (P = 0.022). Patients with aberrant p53 expression in high-grade serous carcinoma (P = 0.012) and patients with high DEF6 expression in clear cell carcinoma (P = 0.001) were also associated with shorter overall survival. In univariate analysis, FIGO stage, DEF6 and p16 were associated with poor prognosis. DEF6 expression was the only independent prognostic factor correlated with shorted OS (HR 2.115; P = 0.025) and DFS (HR 2.248; P = 0.016) upon multivariate analysis. Conclusions: DEF6 expression may serve as an independent prognostic factor, and interacted positively with p16 toward high tumor stage and shorter survival.

AB - Background: Increased expression of DEF6 is correlated with the malignant behavior of various cancers. Both DEF6 and p16 contribute to the regulation of cell cycle progression, and p53 plays important role in the cell cycle checkpoints. This study was designed to elucidate the prognostic significance of DEF6, p53 and p16 immunoexpressions in different histology subtypes of ovarian carcinoma. Methods: Immunohistochemistry results of DEF6, p53 and p16 on ovarian carcinoma were compared with histology subtypes, clinical data, overall survival (OS) and disease-free survival (DFS) by Cox regression and Kaplan-Meier analysis. Results: We studied 180 cases of ovarian carcinomas (75 high-grade serous, 41 clear cell, 36 mucinous and 28 endometrioid), including 109 FIGO stage I-II cases and 71 FIGO stage III-IV cases. Ovarian carcinomas positive for both DEF6 and p16 expression were associated with the worst OS (P = 0.027) and DFS (P = 0.023), whereas those negative for both DEF6 and p16 had the best OS and DFS. Aberrant p53 expression combined with positive DEF6 was associated with worst OS (P = 0.031) and DFS (P = 0.028). Kaplan-Meier analysis showed that significantly shorter survival rates were seen in patients with high expressions of DEF6 (P = 0.008) and p16 (P = 0.022). Patients with aberrant p53 expression in high-grade serous carcinoma (P = 0.012) and patients with high DEF6 expression in clear cell carcinoma (P = 0.001) were also associated with shorter overall survival. In univariate analysis, FIGO stage, DEF6 and p16 were associated with poor prognosis. DEF6 expression was the only independent prognostic factor correlated with shorted OS (HR 2.115; P = 0.025) and DFS (HR 2.248; P = 0.016) upon multivariate analysis. Conclusions: DEF6 expression may serve as an independent prognostic factor, and interacted positively with p16 toward high tumor stage and shorter survival.

KW - DEF6

KW - Ovarian carcinoma

KW - P16

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84988373917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988373917&partnerID=8YFLogxK

U2 - 10.1186/s13000-016-0518-y

DO - 10.1186/s13000-016-0518-y

M3 - Article

C2 - 27488395

AN - SCOPUS:84988373917

VL - 11

JO - Diagnostic Pathology

JF - Diagnostic Pathology

SN - 1746-1596

IS - 1

M1 - 68

ER -